The international consortium of researchers, including experts from the Institute of Myology, which developed SV95C, a digital parameter for the functional evaluation of Duchenne muscular dystrophy (DMD), has announced its adoption by the European Medicines Agency (EMA) as a primary endpoint in therapeutic trials:
- this assessment is based on the analysis of information transmitted by sensors worn by DMD patients,
- This technological innovation, developed by SYSNAV, enables non-invasive measurement of the patient’s movements and displacements,
- SV95C corresponds to the 5% fastest movements of the day,
- The EMA has authorized its use as a major evaluation criterion in future therapeutic trials, from the age of 4 upwards.
This is a first in the field of assessment tools for DMD.
